Neotigason (Acitretin)

Acitretin, the active ingredient in Neotigason, is a retinoid presented as oral tablets for systemic use. It is prescribed for severe psoriasis and related keratinization disorders in adult patients, helping to normalize skin cell growth and reduce plaque formation.

GNH USA supplies Neotigason as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from consistent batch release, comprehensive documentation, and responsive technical support throughout the supply chain.

Neotigason (acitretin) is used in the management of disorders characterized by abnormal keratinocyte proliferation and differentiation.

Severe psoriasis: reduces plaque thickness, scaling and erythema by normalizing epidermal cell turnover. Psoriatic keratoderma: improves hyperkeratosis of palms and soles, decreasing pain and functional impairment. Other severe keratinization disorders: restores regular skin architecture and mitigates excessive keratin buildup.

Acitretin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dry skin: excessive dryness and scaling. - Cheilitis: inflammation and cracking of the lips. - Elevated triglycerides: increase in serum triglyceride levels. - Headache: mild to moderate cephalic pain.

Serious or Rare Side Effects: - Liver toxicity: elevated transaminases or hepatitis. - Pseudotumor cerebri: increased intracranial pressure with visual disturbances. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing acitretin, clinicians should observe several safety measures to minimize risks. - Teratogenic risk: contraindicated in pregnancy; effective contraception required for women of childbearing potential. - Pregnancy contraindication: must not be used by pregnant patients or those planning conception for at least 3 years after discontinuation. - Lipid monitoring: regular assessment of serum triglycerides and cholesterol recommended. - Liver function: periodic liver enzyme tests required to detect hepatotoxicity. - Concomitant vitamin A: avoid additional vitamin A supplements to prevent additive toxicity. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Acitretin can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Tetracyclines: combined use may increase risk of intracranial hypertension. - Vitamin A supplements: additive retinoid toxicity. - Oral contraceptives: acitretin reduces hormonal efficacy, increasing pregnancy risk.

Moderate Interactions (Monitor Closely): - Statins: may exacerbate lipid abnormalities. - Methotrexate: concurrent hepatotoxic potential requires liver function monitoring.